Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143

被引:35
作者
Akao, Yukihiro [1 ]
Kumazaki, Minami [1 ]
Shinohara, Haruka [1 ]
Sugito, Nobuhiko [1 ]
Kuranaga, Yuki [1 ]
Tsujino, Takuya [1 ]
Yoshikawa, Yuki [1 ]
Kitade, Yukio [1 ,2 ]
机构
[1] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan
[2] Aichi Inst Technol, Fac Engn, Dept Appl Chem, Toyota, Japan
关键词
epidermal growth factor receptor; K-Ras; miR-143; Ras inhibitor; Sos1; COLORECTAL-CANCER; MICRORNA-143; ACTS; TUMOR-SUPPRESSOR; TARGETING RAS; CELL-GROWTH; CETUXIMAB; THERAPY; MUTATIONS; KRAS; PATHWAYS;
D O I
10.1111/cas.13559
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite considerable research on K-Ras inhibitors, none had been established until now. We synthesized nuclease-resistant synthetic miR-143 (miR-143#12), which strongly silenced K-Ras, its effector signal molecules AKT and ERK, and the K-Ras activator Sos1. We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations. Cell growth was markedly suppressed in a concentration-dependent manner by miR-143#12 (IC50: 1.32 nmol L-1) with a decrease in the K-Ras mRNA level. Interestingly, this mRNA level was also downregulated by either a PI3K/AKT or MEK inhibitor, which indicates a positive circuit of K-Ras mRNA expression. MiR-143#12 silenced cytoplasmic K-Ras mRNA expression and impaired the positive circuit by directly targeting AKT and ERK mRNA. Combination treatment with miR-143#12 and a low-dose EGFR inhibitor induced a synergistic inhibition of growth with a marked inactivation of both PI3K/AKT and MAPK/ERK signaling pathways. However, silencing K-Ras by siR-KRas instead of miR-143#12 did not induce this synergism through the combined treatment with the EGFR inhibitor. Thus, miR-143#12 perturbed the K-Ras expression system and K-Ras activation by silencing Sos1 and, resultantly, restored the efficacy of the EGFR inhibitors. The in vivo results also supported those of the in vitro experiments. The extremely potent miR-143#12 enabled us to understand K-Ras signaling networks and shut them down by combination treatment with this miRNA and EGFR inhibitor in K-Ras-driven colon cancer cell lines.
引用
收藏
页码:1455 / 1467
页数:13
相关论文
共 42 条
[1]   Role of anti-oncomirs miR-143 and-145 in human colorectal tumors [J].
Akao, Y. ;
Nakagawa, Y. ;
Hirata, I. ;
Iio, A. ;
Itoh, T. ;
Kojima, K. ;
Nakashima, R. ;
Kitade, Y. ;
Naoe, T. .
CANCER GENE THERAPY, 2010, 17 (06) :398-408
[2]   Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells [J].
Akao, Yukihiro ;
Nakagawa, Yoshihito ;
Iio, Akio ;
Naoe, Tomoki .
LEUKEMIA RESEARCH, 2009, 33 (11) :1530-1538
[3]  
Ardekani Ali M., 2010, Avicenna Journal of Medical Biotechnology, V2, P161
[4]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[5]   Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors [J].
Beg, Muhammad S. ;
Brenner, Andrew J. ;
Sachdev, Jasgit ;
Borad, Mitesh ;
Kang, Yoon-Koo ;
Stoudemire, Jay ;
Smith, Susan ;
Bader, Andreas G. ;
Kim, Sinil ;
Hong, David S. .
INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) :180-188
[6]   Stable suppression of tumorigenicity by virus-mediated RNA interference [J].
Brummelkamp, TR ;
Bernards, R ;
Agami, R .
CANCER CELL, 2002, 2 (03) :243-247
[7]   Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange [J].
Burns, Michael C. ;
Sun, Qi ;
Daniels, R. Nathan ;
Camper, DeMarco ;
Kennedy, J. Phillip ;
Phan, Jason ;
Olejniczak, Edward T. ;
Lee, Taekyu ;
Waterson, Alex G. ;
Rossanese, Olivia W. ;
Fesik, Stephen W. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (09) :3401-3406
[8]   Increasing complexity of Ras signaling [J].
Campbell, SL ;
Khosravi-Far, R ;
Rossman, KL ;
Clark, GJ ;
Der, CJ .
ONCOGENE, 1998, 17 (11) :1395-1413
[9]   Role of miR-143 targeting KRAS in colorectal tumorigenesis [J].
Chen, X. ;
Guo, X. ;
Zhang, H. ;
Xiang, Y. ;
Chen, J. ;
Yin, Y. ;
Cai, X. ;
Wang, K. ;
Wang, G. ;
Ba, Y. ;
Zhu, L. ;
Wang, J. ;
Yang, R. ;
Zhang, Y. ;
Ren, Z. ;
Zen, K. ;
Zhang, J. ;
Zhang, C-Y .
ONCOGENE, 2009, 28 (10) :1385-1392
[10]   Drugging the undruggable RAS: Mission Possible? [J].
Cox, Adrienne D. ;
Fesik, Stephen W. ;
Kimmelman, Alec C. ;
Luo, Ji ;
Der, Channing J. .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (11) :828-851